◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksS › SDZ

Sandoz Group AG (SDZ) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-16

Sandoz Group AG (SDZ) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Basel, Switzerland with about 20,000 employees. Its market capitalization is roughly $32 billion. In the fiscal year ended 2025-12-31, SDZ reported $11.2B in revenue and $914M in net income.

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide.

Interactive charts & full statements →

SDZ Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue$11.2B$10.4B$10.0B$9.3B
Gross Profit$5.3B$4.9B$4.6B$4.4B
Operating Income (EBIT)$1.4B$307M$375M$1.2B
Net Income$914M$0M$77M$848M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SDZ Free Cash Flow History

Cash flow2025-12-312024-12-312023-12-312022-12-31
Dividends Paid($315M)($215M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SDZ Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-31
Total Assets$22.0B$19.9B$19.4B$17.6B
Total Liabilities$12.6B$11.7B$10.8B$8.8B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SDZ viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

← SDYAll “S” companiesSEA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.